Clinical Trials
200 trialsAdministering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
National Institutes of Health Clinical Center (CC)
Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
National Institutes of Health Clinical Center (CC)
JIVAN
Aurigene Discovery Technologies Limited
Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer
The University of Texas Health Science Center at San Antonio
TOGAR
Baylor College of Medicine
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
Pfizer
PLATON
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.
Novartis
SURGIGAST
University Hospital, Lille
(VELA) Study of BLU-222 in Advanced Solid Tumors
Blueprint Medicines Corporation
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
Elevation Oncology
MK-2140-002
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers
Amgen
DisTinGuish
Leap Therapeutics, Inc.
Futibatinib in Patients With Specific FGFR Aberrations
Taiho Oncology, Inc.
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Bolt Biotherapeutics, Inc.
Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors
Sanofi
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
3B Pharmaceuticals GmbH
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
AM-003
University of Virginia
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
Lithium
Cancer Trials Ireland
NeoRacing
Fudan University
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Pfizer
nextHERIZON
Imugene Limited
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
IVANS
Fondazione IRCCS Policlinico San Matteo di Pavia
MasterKey-01
Black Diamond Therapeutics, Inc.
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Kymab Limited
TOASTIT
Mayo Clinic
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Seagen Inc.
A Study of SGN-ALPV in Advanced Solid Tumors
Seagen Inc.
A Study of SGN-STNV in Advanced Solid Tumors
Seagen Inc.
FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
Pfizer
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Celularity Incorporated
RESCUE-GC
Peking University Cancer Hospital & Institute
Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis
Highlight Therapeutics
A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
Hoffmann-La Roche
PECORINO
Ukrainian Society of Clinical Oncology
Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer
Huazhong University of Science and Technology
CAR
Shanghai PerHum Therapeutics Co., Ltd.